Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 h...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Simmons, John K., Michalowski, Aleksandra M., Gamache, Benjamin J., DuBois, Wendy, Patel, Jyoti, Zhang, Ke, Gary, Joy, Zhang, Shuling, Gaikwad, Snehal, Connors, Daniel, Watson, Nicholas, Leon, Elena, Chen, Jin-Qiu, Kuehl, W. Michael, Lee, Maxwell P., Zingone, Adriana, Landgren, Ola, Ordentlich, Peter, Huang, Jing, Mock, Beverly A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587368/
https://ncbi.nlm.nih.gov/pubmed/28522584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0171
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi